Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years because of the United States' demand for sensitive information.
The decision was revealed after a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman has since stated that the US was requesting biological samples for scientific study and commercial gain but refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more dialogue to find a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision follows a comparable situation in Kenya, where a high court suspended a related deal with the US following concerns were raised about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral deals to enhance transparency and accountability.
As per reports, Sixteen African countries have to date agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, without any corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research with no assurance that the end products would be available to our people should a new disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining frameworks already set up via the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is intended to ensure that when a country contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to create them."
These objections over the US deal "are not meant as opposition to America," he added.
"We welcome continued dialogue with our US partners on how subsequent collaboration could be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but suggested that talks must proceed since a large portion of the country's Aids initiatives relied on external financing.
"Where technical issues arise, such as those involving information security or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it said.
The situation underscores the ongoing debate between receiving much-needed international aid and safeguarding a country's data in an ever more data-driven world.